Hemovent develops MOBYBOX, a self-contained, fully integrated ExtraCorporeal Membrane Oxygenation (ECMO/ECLS) system designed to support or replace heart and lung function. MOBYBOX is CE‑marked and approved for sale in Europe, but is not approved for distribution outside the European Union. The company positions MOBYBOX around ease of use, mobility and high performance as advantages versus standard of care. Hemovent describes itself as having a proprietary platform technology for heart- and lung-support and is pursuing a phased market introduction. The company plans post-market clinical follow-up (PMCF) studies in select clinical settings across Europe as part of its rollout. Recent financing activity is intended to accelerate the market introduction and clinical follow-up of MOBYBOX. Hemovent is an emerging medical device company based in Aachen, Germany, with a proprietary platform for heart and lung support. Its core product, the MOBYBOX™ System, is a self-contained, fully integrated ECMO/ECLS device designed for safety, ease of use, mobility, and performance to support or replace heart and lung function. Hemovent closed a $5.2 million Series B financing round to fund roll-out and regulatory activities. Management expects EU regulatory approval this year and says the funding provides sufficient resources to commence roll-out upon CE approval and to seek FDA clearance in due course. The company has been certified under ISO 13485:2016, which it describes as the next-to-last step in the CE marking process, and completed a GLP standardized in vivo 7-day study for long-term use. The MOBYBOX™ System is not yet approved for human use. Hemovent develops an Extra Corporeal Membrane Oxygenation (ECMO) system that the company describes as the world's smallest, fully portable device to support or replace heart or lung function. Because the devices are about one-tenth the size of similar technologies, they enable easier transport of patients from emergency sites or between hospitals. Hemovent says its systems also cost roughly half the price of comparable devices. The company reports positive in‑vivo experiments carried out since April. Management has stated it wants to bring the solution to market quickly and is seeking CE certification prior to commercial launch. Financially, Hemovent completed a €2 million expansion of a Series A that was €6 million in February 2016. Hemovent is a venture-backed medical device company developing novel, portable artificial lung technologies for applications ranging from Extracorporeal CO2 Removal to ExtraCorporeal Life Support. The company has developed small, self-contained fully portable artificial lungs intended for ECMO/ECLS to support or replace heart and lung function during cardiac and/or respiratory failure. Hemovent plans to use the grant funding to accelerate development of these portable artificial lung systems. The company is led by co-founder and CEO Christof Lenz and co-founder and CTO Oliver Marseille, Ph.D. Hemovent is based in Aachen, Germany and is backed by a group of investors. Its current financial news includes receipt of a government grant totaling $810k to support R&D efforts. Hemovent is an emerging medical device company based in Aachen, Germany, developing the world’s smallest, self-contained and fully portable Extra Corporeal Membrane Oxygenation (ECMO) system. The device is designed to reduce the footprint of ECMO therapy by about 90%, weighs roughly two pounds, and the company says it requires neither battery nor software. Hemovent describes the system as extremely robust and operating like a natural heart, intended to simplify patient transport and mobilization during treatment. Management and investors position the portable form factor as a way to broaden ECMO use by addressing current technology’s complexity, cost and lack of portability. The article states ECMO markets are growing rapidly and Hemovent aims to make ECMO deployment easier and more cost-effective. Hemovent closed a $6 million Series A to advance its product development and commercialization efforts.

Total raised

$20M

Funding rounds

5

Latest round

Series B

Latest activity

Jul 2020